Zu Xu Yao
Plus aucun poste en cours
Profil
Zu Xu Yao worked as an Associate Director at Adnavance Technologies, Inc. and as the Chief Scientific Officer at DermTech Operations, Inc. from 2017 to 2019.
Prior to that, he was the Chief Scientific Officer at DermTech, Inc. He also worked as the Vice President-Assay Development at Nexogen, Inc. from 2012 to 2014.
Yao holds a doctorate degree from Memorial University of Newfoundland, an undergraduate degree from Xiamen University, and a graduate degree from Wageningen University.
Anciens postes connus de Zu Xu Yao
| Sociétés | Poste | Fin |
|---|---|---|
DermTech Operations, Inc.
 DermTech Operations, Inc. Medical SpecialtiesHealth Technology DermTech Operations, Inc. engages in the provision of molecular dermatology. It develops products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. The firm's products include adhesive skin collection kit, pigmented lesion assay (PLA), nevome, inflammatory disease and carcinome. The company was founded by Lawrence A. Rheins in 1996 and is headquartered in La Jolla, CA. | Directeur Technique/Scientifique/R&D | 01/08/2019 |
| Nexogen, Inc. | Corporate Officer/Principal | 01/10/2014 |
Adnavance Technologies, Inc.
 Adnavance Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Adnavance is a molecular diagnostic company focused on development of DNA-based tests using the Company's patented metalized DNA (M-DNA) platform. The Company is headquartered in Vancouver, British Columbia and also maintains a DNA development laboratory in San Diego, CA. M-DNA is based on the conducting properties of hybridized DNA. Under strict reaction conditions, certain metal ions can enter the central core of hybridized DNA and displace the hydrogen bonds forming the equivalent of a metal wire in the center of the DNA and making the DNA highly conductive. The Company uses a microarray of 10-micron electrodes to detect the M-DNA and the inherent ultra-sensitivity arises from the differential change in conductivity between hybridized DNA and metalized DNA. This change in conductivity is so large that it obviates the need for target amplification used in current molecular-based tests. Adnavance scientists were the first to discover the M-DNA phenomenon, and the Company believes its technology platform will open new molecular testing markets. | Corporate Officer/Principal | - |
| DERMTECH, INC. | Directeur Technique/Scientifique/R&D | - |
Formation de Zu Xu Yao
| Memorial University of Newfoundland | Doctorate Degree |
| Xiamen University | Undergraduate Degree |
| Wageningen University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| DERMTECH, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
DermTech Operations, Inc.
DermTech Operations, Inc. Medical SpecialtiesHealth Technology DermTech Operations, Inc. engages in the provision of molecular dermatology. It develops products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. The firm's products include adhesive skin collection kit, pigmented lesion assay (PLA), nevome, inflammatory disease and carcinome. The company was founded by Lawrence A. Rheins in 1996 and is headquartered in La Jolla, CA. | Health Technology |
Adnavance Technologies, Inc.
Adnavance Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Adnavance is a molecular diagnostic company focused on development of DNA-based tests using the Company's patented metalized DNA (M-DNA) platform. The Company is headquartered in Vancouver, British Columbia and also maintains a DNA development laboratory in San Diego, CA. M-DNA is based on the conducting properties of hybridized DNA. Under strict reaction conditions, certain metal ions can enter the central core of hybridized DNA and displace the hydrogen bonds forming the equivalent of a metal wire in the center of the DNA and making the DNA highly conductive. The Company uses a microarray of 10-micron electrodes to detect the M-DNA and the inherent ultra-sensitivity arises from the differential change in conductivity between hybridized DNA and metalized DNA. This change in conductivity is so large that it obviates the need for target amplification used in current molecular-based tests. Adnavance scientists were the first to discover the M-DNA phenomenon, and the Company believes its technology platform will open new molecular testing markets. | Commercial Services |
| Nexogen, Inc. |
